In this study, we are trying to see if vitamin B6 can minimize the amplified blood pressure response to exercise following ischemia-reperfusion injury. We are interested in a protein called P2X3, of which function can be blocked by vitamin B6, in the neurons of our nervous system. It is very important for blood pressure regulation. We would like to see if the P2X3 plays a role in patients' rising blood pressure during exercise. The results of the proposed studies will provide a base for those two potential economic and non-invasive inventions to improve the overall health and well-being of PAD patients.

Start Date01 Dec 2025

Sponsor / Collaborator

Hershey Medical Center

[+1]

CTIS2023-505155-47-00

/ RecruitingPhase 2IIT

Pyridoxine in primary sclerosing cholangitis - 1.1

Start Date24 Oct 2024

Sponsor / Collaborator-

IRCT20240911063006N1

/ RecruitingPhase 3IIT

Assessing the Impact of Pre-spinal Anesthesia Intravenous Vitamin B6 Injections on Post-Cesarean Nausea and Vomiting

Start Date22 Sep 2024

Sponsor / Collaborator

Mashhad University of Medical Sciences

100 Clinical Results associated with Pyridoxine Hydrochloride

100 Translational Medicine associated with Pyridoxine Hydrochloride

100 Patents (Medical) associated with Pyridoxine Hydrochloride

18,530

Literatures (Medical) associated with Pyridoxine Hydrochloride

31 Dec 2025·Gut Microbes

Gut dysbiosis-induced vitamin B6 metabolic disorder contributes to chronic stress-related abnormal behaviors in a cortisol-independent manner

Article

Author: Qing, Wenxiang ; Tong, Jianhua ; Ma, Xin ; Chen, Jie ; Le, Yuan ; Ma, Daqing ; Chen, Huimin ; Ouyang, Wen ; Tong, Jianbin ; Duan, Kaiming ; Chen, Hui

Chronic stress can result in various conditions, including psychological disorders, neurodegenerative diseases, and accelerated brain aging. Gut dysbiosis potentially contributes to stress-related brain disorders in individuals with chronic stress. However, the causal relationship and key factors between gut dysbiosis and brain disorders in chronic stress remain elusive, particularly under non-sterile conditions. Here, using a repeated restraint stress (RRS) rat model, we show that sequential transplantation of the cecal contents of different RRS stages to normal rats reproduced RRS-induced core phenotypes, including abnormal behaviors, increased peripheral blood corticosterone and inflammatory cytokines, and a unique gut microbial phenotype. This core phenotypic development was effectively inhibited with probiotic supplement. The RRS-induced unique gut microbial phenotypes at the genus level were positively or negatively associated with the levels of 20 plasma metabolites, including vitamin B6 metabolites 4-pyridoxic acid and 4-pyridoxate. Vitamin B6 supplement during RRS alleviated weight loss, abnormal behaviors, peripheral inflammation, and neuroinflammation, but did not affect the peripheral corticosterone levels in chronic stressed rats. Dampening inflammatory signaling via knocking out caspase 11 or caspase 1 inhibitor abolished RRS-induced abnormal behaviors and peripheral and neuroinflammation but did not decrease peripheral corticosterone in mice. These findings show that gut dysbiosis-induced vitamin B6 metabolism disorder is a new non-hypothalamic-pituitary-adrenal axis mechanism of chronic stress-related brain disorders. Both probiotics and vitamin B6 supplement have potential to be developed as therapeutic strategies for preventing and/or treating chronic stress-related illness.

01 Apr 2025·Food Chemistry

Multidimensional analysis of the flavor characteristics of yellow peach at different ripening stages: Chemical composition profiling and sensory evaluation

Article

Author: Zeng, Wenfang ; Ye, Zhengwen ; Li, Xiongwei ; Zhou, Huijuan ; Su, Mingshen ; Yang, Xiaofeng ; Du, Jihong ; Wang, Shouchuang ; Liu, Huayu ; Zhang, Xianan ; Zhang, Minghao

The flavor evolution of yellow peaches during ripening was investigated using a gas chromatography-mass spectrometer (GC-MS), metabolomics, and electronic sensoristic techniques. Of the 41 volatiles quantified, 13 increased the intensity of the aroma based on the odor activity values (OAVs). Additionally, 142 non-volatile compounds were identified. Metabolic pathway analysis indicated that the formation of xanthophyll esters, due to substrate competition, resulted in a reduction of carotenoid-derived volatiles. Electronic nose (E-nose) analysis revealed that the key sensor W1C-associated volatiles had a green aroma, while W1S and W2S-associated volatiles showed a fruity aroma. Electronic tongue (E-tongue) analysis revealed that L-norleucine, L-isoleucine, isoleucine, L-tyrosine, L-valine, 4-Hydroxybenzaldehyde, cinnamic acid, and rutin positively correlated with umami and sweetness. Conversely, cis-aconitic acid and (-)-epigallocatechin positively correlated with sourness or astringency. Moreover, 20 volatiles, including γ-decalactone, linalool, and (Z)-3-hexenyl acetate, were positively correlated with umami or sweetness, while 7 volatiles were positively correlated with sourness or astringency.

01 Apr 2025·The American Journal of Emergency Medicine

Acute kidney failure from ingestion of “wood bleach” beekeeping miticide

Article

Author: Olives, Travis D ; Oakland, Carrie L ; Douglas, Stephen ; Cole, Jon B

Wood bleach is >95 % oxalic acid formulation used off-label as a miticide for Varroa mites by hobbyist beekeepers. Wood bleach (oxalic acid) ingestions are poorly documented in the medical literature. A 46-year-old man presented to the emergency department nauseated and vomiting after accidentally ingesting "bleach and grain ethanol intended for use in beekeeping." Initial evaluation was reported to the regional Poison Center as a creatinine concentration of 2.46 mg/dL (217 μmol/L); he was otherwise well. He was volume resuscitated and discharged home without further evaluation. Four days later, he returned with worsening nausea and vomiting, endorsing ongoing intentional use of the mixture as an intoxicant. He was fully oriented, in no distress, with normal vital signs but for blood pressure of 175/110 mmHg. Investigations revealed a serum creatinine of 16.8 mg/dL (1485 μmol/L) and a high anion gap metabolic acidosis (pH 7.3, bicarbonate 15 mmol/L, anion gap 29). Crystalluria testing was deferred due to anuria. Fomepizole, supplementary thiamine and pyridoxine were administered for suspected occult toxic alcohol poisoning; hemodialysis was initiated the same evening. Ethylene glycol resulted undetectable. Renal biopsy revealed oxalate nephropathy. It was revealed the mixture contained 'wood bleach,' or > 95 % oxalic acid, rather than reported sodium hypochlorite. Hemodialysis continued at 2-week follow-up. Presentations of anion gap metabolic acidosis in those who practice beekeeping should prompt consideration of oxalic acid toxicity. Early nephrology consultation may be needed to facilitate hemodialysis to prevent or treat metabolic acidosis and renal failure.

News (Medical) associated with Pyridoxine Hydrochloride

02 Jan 2025

·www.prnewswire.com

First of Its Kind Gene Therapy Model Offers Hope for X-Linked Sideroblastic Anemia Treatment

New model and vector could be instrumental in transforming the lives of XLSA patients and those with a broad spectrum of other diseases PHILADELPHIA, Jan. 2, 2025 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine pioneered a first of its kind gene therapy model that offers a potential breakthrough in treating X-linked sideroblastic anemia (XLSA), a rare congenital anemia caused by mutations in the ALAS2 gene crucial for the synthesis of heme, a key compound in hemoglobin. This study marks the first time researchers studied gene therapy to treat this disease, which the authors underscore could have an impact on a broad spectrum of diseases. The research was published today and featured on the cover of the journal Blood. XLSA has traditionally impacted men under the age of 40, however, researchers noted that new cases of girls and mid-life women with the rare disease are beginning to emerge. Patients with XLSA experience a disruption in heme synthesis, leading to a spectrum of issues such as severe anemia and iron overload, which can cause symptoms like extreme fatigue, shortness of breath and growth delays. Most XLSA patients are dependent on pyridoxine supplements, which provide vitamin B6, and blood transfusions to treat the disease. The sole potential cure for XLSA is currently an allogenic stem cell transplant, which is only an option for a limited number of patients due to the need for a compatible donor, high cost and intense chemotherapy involved, which can have significant side effects. In this study, researchers used a newly created preclinical model to evaluate for the first time whether gene therapy could offer a potentially transformative treatment for these patients. Carlo Castruccio Castracani, PharmD, PhD, the study's lead author and the team's Clinical Research Study Manager, used a targeted lipid nanoparticle (LNP) platform technology, established by Hamideh Parhiz, PharmD, PhD, a co-senior study author and Assistant Professor of Pharmacology at Penn Medicine, to induce the deletion of the Alas2 gene in hematopoietic stem cells. Upon deletion of the ALAS2 gene, the researchers subsequently observed classic symptoms of XLSA like anemia and enlargement of the spleen. The model also allowed the researchers to note features of this disease that are significant in humans, such as ring sideroblasts, a type of immature red blood cell. "The lack of ALAS2 in the preclinical model was associated with an expansion in the number of premature red cells, with a high proportion undergoing cell death," said Castruccio Castracani. "We also observed defects in metabolism and mitochondria structure and performance, which prevented healthy red cells from forming and led to severe anemia." Castruccio Castracani and his team developed a lentiviral vector that activated the human ALAS2 gene in erythroid cells, or cells that serve as precursors to normal red blood cells. They found that this gene therapy approach significantly boosted hemoglobin and red blood cell levels, helping normalize hormone levels that control red blood cell production. Preclinical trial subjects that received optimal doses of the vector showed significant improvements in hemoglobin levels, spleen health, and iron balance. "This new model and vector may hold the keys to transforming the lives of XLSA patients," said Stefano Rivella, PhD, a senior author, the Kwame Ohene-Frempong Endowed Chair in Pediatric Hematology research and a faculty member in the Division of Hematology at CHOP. "In future studies, we aim to adapt this model to investigate pharmacological treatment and in vivo gene editing for a broader range of diseases." Castruccio Castracani et al. "An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA." Blood. January 2, 2025. DOI: 10.1182/blood.2024025846. About Children's Hospital of Philadelphia: A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey, as well as the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia. In addition, its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit . Contact: Jennifer Lee Children's Hospital of Philadelphia (267) 426-6084 [email protected] SOURCE Children's Hospital of Philadelphia WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Gene TherapyClinical Study

10 Oct 2024

·www.prnewswire.com

Duchesnay Pharmaceutical Group celebrates expansion of its treatment portfolio for nausea and vomiting of pregnancy to 40 countries around the world

Achievement highlights continued growth of Quebec-based business BLAINVILLE, QC, Oct. 10, 2024 /PRNewswire/ - Duchesnay Pharmaceutical Group (DPG), one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project, is very proud to announce that its treatment portfolio for nausea and vomiting of pregnancy (NVP) global footprint has now expanded to include additional regulatory approvals in over 40 countries around the world. Continue Reading DPG celebrates expansion of its NVP treatment portfolio to 40 countries around the world (CNW Group/Duchesnay Pharmaceutical Group (DPG)) Developed, patented and manufactured locally at DPG's state-of-the-art facility in Blainville, Quebec, this unique product portfolio consists of the combination of doxylamine succinate and pyridoxine hydrochloride, available in different strengths and formulations under different trade names (such as Xonvea® and Bonjesta®) around the world. "This portfolio has a 40-year history of safe use by pregnant women to manage and treat NVP, often referred to as 'morning sickness,'" said Michael Gallo, Vice-President, Regulatory & Medical Affairs, Duchesnay Pharmaceutical Group. "In fact, the recognition of nausea and vomiting of pregnancy as a medical condition is a result of the efforts of the Duchesnay team, who have pioneered the scientific landscape around this serious condition since the early 2000s." This combination of doxylamine succinate and pyridoxine hydrochloride has already received market authorization in an additional 13 countries in 2024 with new approvals expected in the short term and for several years to come. "We are very proud of this accomplishment, and it would not be possible without the commitment of our teams and the collaboration and dedication of our international partners,'' said Suzanne Paszkiewicz, Vice-President, Global Partnerships & Business Development, Duchesnay Pharmaceutical Group. "The issue of NVP and the lack of approved treatment options is a universal one, therefore we are committed to continuing to address this medical need around the world." ABOUT DUCHESNAY PHARMACEUTICAL GROUP Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries. DPG is one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate its growth to become an anchor firm in the Canadian economy. DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare and debilitating diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations. For more information, please visit . SOURCE Duchesnay Pharmaceutical Group (DPG) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

26 Sep 2024

·www.globenewswire.com

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Company to host conference call today at 4:30 p.m. ETSAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). The voluntary enrollment pause enables the Company to work to address necessary process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study. Patients currently enrolled in pegtibatinase studies continue to receive study medication from small scale batches which are unaffected by the scale-up process. Currently enrolled patients will be able to continue on study medication as scheduled for the duration of the trials they are participating in. The voluntary enrollment pause was enacted following the Company’s determination that the desired drug substance profile was not achieved in the recent scale-up process. The Company is in the process of notifying all study investigators of the decision to pause enrollment of new patients into the study until additional material is available. “We believe the potential for pegtibatinase to become the first disease-modifying therapy for classical HCU remains unchanged. Our internal team and external manufacturing partners have extensive biologics expertise, and we are confident that we will be able to make the necessary manufacturing process improvements to continue with this pivotal program. We remain committed to supporting the patients currently enrolled in our clinical trials while working with our manufacturing partners to optimize our commercial-scale manufacturing process,” said Bill Rote, Ph.D., senior vice president of research and development at Travere Therapeutics. The Company expects to further evaluate the necessary commercial process improvements to enable the continuation of the Phase 3 program and anticipates the earliest date to restart enrollment in the Phase 3 HARMONY Study will be in 2026. Previously planned investments related to clinical enrollment in HARMONY and large-scale production are expected to be delayed beyond 2025. Together with the expected decline in costs associated with the development of sparsentan as the Phase 3 programs advance towards completion, the Company now estimates that research and development expenses may be reduced by more than $30 million in 2025 compared to 2024. The Company continues to anticipate that its cash, cash equivalents and marketable securities of $325.4 million as of June 30, 2024 can support its operations into 2028. Conference call information Travere Therapeutics will host a conference call and webcast today, Thursday, September 26, 2024 at 4:30 p.m. ET to discuss the voluntary pause in enrollment. To participate in the conference call, dial +1 (323) 994-2093 (U.S.) or +1 (888) 394-8218 (International), confirmation code 5880214. The webcast can be accessed on the Investor page of Travere’s website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website. About Classical Homocystinuria Classical homocystinuria (HCU) is a rare genetic metabolic disorder caused by a deficiency in the enzyme cystathionine beta synthase (CBS). CBS is a pivotal enzyme that is essential for the management of methionine and cysteine in the body. Classical HCU leads to toxic levels of homocysteine that can result in life-threatening thrombotic events such as stroke, pulmonary embolism and deep vein thrombosis, ophthalmologic and skeletal complications, as well as developmental delay. Current treatment options are limited to protein-restricted diet and use of vitamin B6 and betaine. About Pegtibatinase Pegtibatinase is an investigational PEGylated, recombinant enzyme replacement therapy designed to address the underlying cause of classical HCU. In preclinical studies, pegtibatinase has demonstrated an ability to reduce total homocysteine levels and improve clinical parameters. In December 2023 the Company initiated the pivotal Phase 3 HARMONY Study to support the potential approval of pegtibatinase for the treatment of classical HCU. The HARMONY Study is a global, randomized, multi-center, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy and safety of pegtibatinase as a novel treatment to reduce total homocysteine (tHcy) levels. In May 2023 the Company announced that data from four patients treated with the highest dose of pegtibatinase in the Phase 1/2 COMPOSE Study showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment. To date, the pegtibatinase program has been granted Breakthrough Therapy designation, Rare Pediatric Disease and Fast Track designations by the FDA, as well as Orphan Drug designation in the U.S. and Europe. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com. Forward-Looking Statements This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “on-track,” “positioned,” “look forward to,” “will,” “would,” “may,” “might,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: the potential for pegtibatinase to become the first disease-modifying therapy for classical HCU; statements and expectations regarding future process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study, and related timing expectations; statements regarding ongoing clinical trials, including statements regarding medication for patients currently enrolled in such trials; and statements and expectations related to future research and development expenses and the expected timing thereof, including with respect to investments related to clinical enrollment in HARMONY and large scale production, and the expected decline in costs associated with the development of sparsentan as the Phase 3 programs advance towards completion; and expectations regarding cash runway. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with manufacturing processes and improvements, and risks related to the regulatory review and approval process, as well as risks and uncertainties associated with the Company’s business and finances in general, the success of its commercial products and risks and uncertainties associated with its preclinical and clinical stage pipeline. Specifically, the Company faces risks associated with the challenges of manufacturing scale-up, the ongoing commercial launch of FILSPARI, market acceptance of its commercial products including efficacy, safety, price, reimbursement, and benefit over competing therapies, as well as risks associated with the successful development and execution of commercial strategies for such products. The risks and uncertainties the Company faces with respect to its preclinical and clinical stage pipeline include risk that the Company’s clinical candidates will not be found to be safe or effective and that current or anticipated future clinical trials will not proceed as planned. The Company also faces the risk that its cash runway might not last as long as currently anticipated and the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions; risks relating to the Company’s dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company’s products, and technological changes that may limit demand for the Company’s products. The Company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission. Contact Info Media:888-969-7879 mediarelations@travere.comInvestors:888-969-7879 IR@travere.com

Phase 3Fast TrackBreakthrough TherapyOrphan DrugClinical Result

100 Deals associated with Pyridoxine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Pyridoxine Hydrochloride	A11HA02	DB00165

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Vitamin B 6 Deficiency	United States	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bipolar I disorder	Phase 2	United States	McLean Hospital, Inc.	13 Dec 2023
Progressive fibrotic interstitial lung disease	Phase 1	China	Shanxi Bethune Hospital	01 Mar 2024
Protoporphyria, Erythropoietic, X-Linked Dominant	Preclinical	United States	Harvard Medical School	05 Nov 2021
X-Linked Sideroblastic Anemia	Preclinical	United States	Harvard Medical School	05 Nov 2021
Parkinson Disease	Preclinical	China	Nanjing Medical University	18 Feb 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACAAI2024	Not Applicable	-	-	Vitamin B6	wmajwsyvox(ooycbhtjtl) = vekgcgjzee nuoqgpyefe (pqdzthtilb )	-	24 Oct 2024
NCT05024422 (Pubmed \| Am J Obstet Gynecol)	Phase 3	Breast Feeding	-	Cabergoline	cmxesblzik(mwvrpmtson) = gzcxhtnawi daqjiqrjms (nuhupsqfyv ) View more	Positive	01 May 2024
				Pyridoxine	cmxesblzik(mwvrpmtson) = gxkutvvchl daqjiqrjms (nuhupsqfyv ) View more
NCT03510468 (CTgov)	Phase 1	-	51	Tenofovir alafenamide+Rifapentine+Pyridoxine+Isoniazid (INH)	ueemrossay(kztwsavqfv) = xhplktwies cytszetfyq (fxtmwampmw, ywbxujnhtm - jadnpibodq) View more	-	25 Oct 2023
EADV2023	Not Applicable	-	61	Oral biotin	szpkelxyfp(hdcdqhctny) = earijjmzvo ujtmvbcbew (dlmlwwgwct ) View more	Positive	11 Oct 2023
				Pyridoxine	szpkelxyfp(hdcdqhctny) = fvccvgnmyf ujtmvbcbew (dlmlwwgwct ) View more
NCT03882177 (StAT-TB, CTgov)	Phase 2	Pulmonary Tuberculosis	16	Pravastatin+Vitamin B6+Rifafour (Arm 1: Pravastatin (40 mg) and Rifafour)	(qawunrppmc) = czskrvpdar flegejlzkt (hmrdbcziej, rdqtuzbanm - rpxbgjdwdo) View more	-	18 Sep 2023
				Vitamin B6+Pravastatin+Rifafour (Arm 2: Pravastatin (80 mg) and Rifafour)	(qawunrppmc) = bpyrqiwtqz flegejlzkt (hmrdbcziej, vmxxibkbvr - tykjhfqvfk) View more
DDW2022	Not Applicable	Inflammatory Bowel Diseases	-	VITAMIN B6 (Patients with inflammation)	rvquwetjfy(ybrudstazj) = zbgzfhrvfc gdpyemovad (uhrlqqtmuz, 1.9 - 46.0) View more	-	24 May 2022
				VITAMIN B6 (Patients without inflammation)	rvquwetjfy(ybrudstazj) = zmeixwfhsw gdpyemovad (uhrlqqtmuz, 0.1 - 88.0) View more
Alienor Study (ARVO2022)	Not Applicable	Age Related Macular Degeneration	963	Vitamin B5	ovxkfyywpx(jcihnqeyoq) = lszwdtfmzi eelwokbfpl (syyggabrob, 1.84mg)	-	01 May 2022
				Vitamin B6	ovxkfyywpx(jcihnqeyoq) = yymyquhrpw eelwokbfpl (syyggabrob, 0.60mg)
compassionate use (ASN2021)	Not Applicable	Primary Hyperoxaluria Type 1 Maintenance	2	Pyridoxine	(vjctspwnur) = qetdycvuiw kzctbfazwq (uqoubgbtms )	Positive	27 Oct 2021
Rare Kidney Stone Consortium PH Registry (ASN2020)	Not Applicable	Primary Hyperoxaluria Type 1 G170R homozygous	3	Pyridoxine	zrsuzhphsh(xpadihgqei) = xegljbkrcj jvxxuswims (cjkvglljxo )	Positive	19 Oct 2020
ASN2019	Not Applicable	Hemodialysis complication alanine aminotransferase (ALT)	-	Pyridoxine IV	(vxqkjsouvv) = fereafykwg gzccsdpbcx (ptibpyorfb )	Positive	05 Nov 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis